GSK gets approval in China for Nucala
Type a few symbols and Take a Trial. The signals for these will appear immediately on your My Stocks Page; add more too.
Shares of GSK PLC GSK rose 1.11% to £13.62 Thursday, on what proved to be an all-around favorable trading session for the ...
On Friday, GSK plc (GSK) stock saw a decline, ending the day at $33.47 which represents a decrease of $-0.48 or -1.41% from the prior close of $33.95. The stock opened at $33.98 and touched a low of ...
GSK took center stage last month, forming standout partnerships and alliances across multiple therapeutic areas.
Belantamab mafodotin is under clinical development by GSK and currently in Phase I for Systemic Lupus Erythematosus.
Which biotechs are most likely to be acquired near-term? We asked Seeking Alpha analysts Edmund Ingham and Terry Chrisomalis for their thoughts on the topic. Read more here.
Welcome to Fierce Pharma's regulatory tracker for the first half of 2025. | In this tracker, Fierce Pharma is recording the ...
GlaxoSmithKline ( (GSK) ) has provided an update. GSK announced that its monoclonal antibody, Nucala (mepolizumab), has been approved in China for treating adults with chronic rhinosinusitis with ...
GSK -4178116 (GSK4178116A) is under development for the prevention of varicella (chickenpox) caused by the new strain (US) of varicella-zoster virus (VZV). It is administered through subcutaneous ...
Drugmaker GSK said, a stamp has been released by India Post to commemorate its 100 years in India. The ₹5 denomination stamp ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback